Cargando…
Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges
Cancer is a top global public health concern. At present, molecular targeted therapy has emerged as one of the main therapies for cancer, with high efficacy and safety. The medical world continues to struggle with the development of efficient, extremely selective, and low-toxicity anticancer medicat...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305175/ https://www.ncbi.nlm.nih.gov/pubmed/37376154 http://dx.doi.org/10.3390/pharmaceutics15061706 |
_version_ | 1785065671496826880 |
---|---|
author | Liu, Junxia Chao, Tengfei Liu, Yingying Gong, Chen Zhang, Yinan Xiong, Huihua |
author_facet | Liu, Junxia Chao, Tengfei Liu, Yingying Gong, Chen Zhang, Yinan Xiong, Huihua |
author_sort | Liu, Junxia |
collection | PubMed |
description | Cancer is a top global public health concern. At present, molecular targeted therapy has emerged as one of the main therapies for cancer, with high efficacy and safety. The medical world continues to struggle with the development of efficient, extremely selective, and low-toxicity anticancer medications. Heterocyclic scaffolds based on the molecular structure of tumor therapeutic targets are widely used in anticancer drug design. In addition, a revolution in medicine has been brought on by the quick advancement of nanotechnology. Many nanomedicines have taken targeted cancer therapy to a new level. In this review, we highlight heterocyclic molecular-targeted drugs as well as heterocyclic-associated nanomedicines in cancer. |
format | Online Article Text |
id | pubmed-10305175 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103051752023-06-29 Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges Liu, Junxia Chao, Tengfei Liu, Yingying Gong, Chen Zhang, Yinan Xiong, Huihua Pharmaceutics Review Cancer is a top global public health concern. At present, molecular targeted therapy has emerged as one of the main therapies for cancer, with high efficacy and safety. The medical world continues to struggle with the development of efficient, extremely selective, and low-toxicity anticancer medications. Heterocyclic scaffolds based on the molecular structure of tumor therapeutic targets are widely used in anticancer drug design. In addition, a revolution in medicine has been brought on by the quick advancement of nanotechnology. Many nanomedicines have taken targeted cancer therapy to a new level. In this review, we highlight heterocyclic molecular-targeted drugs as well as heterocyclic-associated nanomedicines in cancer. MDPI 2023-06-10 /pmc/articles/PMC10305175/ /pubmed/37376154 http://dx.doi.org/10.3390/pharmaceutics15061706 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Liu, Junxia Chao, Tengfei Liu, Yingying Gong, Chen Zhang, Yinan Xiong, Huihua Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges |
title | Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges |
title_full | Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges |
title_fullStr | Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges |
title_full_unstemmed | Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges |
title_short | Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges |
title_sort | heterocyclic molecular targeted drugs and nanomedicines for cancer: recent advances and challenges |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305175/ https://www.ncbi.nlm.nih.gov/pubmed/37376154 http://dx.doi.org/10.3390/pharmaceutics15061706 |
work_keys_str_mv | AT liujunxia heterocyclicmoleculartargeteddrugsandnanomedicinesforcancerrecentadvancesandchallenges AT chaotengfei heterocyclicmoleculartargeteddrugsandnanomedicinesforcancerrecentadvancesandchallenges AT liuyingying heterocyclicmoleculartargeteddrugsandnanomedicinesforcancerrecentadvancesandchallenges AT gongchen heterocyclicmoleculartargeteddrugsandnanomedicinesforcancerrecentadvancesandchallenges AT zhangyinan heterocyclicmoleculartargeteddrugsandnanomedicinesforcancerrecentadvancesandchallenges AT xionghuihua heterocyclicmoleculartargeteddrugsandnanomedicinesforcancerrecentadvancesandchallenges |